Authors
Latest:
Three Ways President Trump's FDA Can Help Cure CancerCuring cancer is not an impossibility anymore. Essential to any effort to achieve this will be the policies coming from President Trump’s administration, writes James Nathanielsz.
Latest:
Preparing For the New ChinaChina's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt.
Latest:
Unlocking value and cost savings in patient services with technology and talentTraci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
Latest:
Why Identity is Imperative for Pharma CompaniesPharma must develop digital identity strategies for creating seamless, safe and compliant customer journeys, writes Jamie Beckland.
Latest:
Marketing During the COVID-19 CrisisAn overview of marketing during the COVID-19 crisis and how to utilize various tactical solutions to successfully reach your targeted healthcare professional audiences.
Latest:
The New Age of BioDigital PharmaIt’s no longer sufficient for a pharma to develop better products or even build simple apps. The industry increasingly needs to create sophisticated predictive algorithms to maximize the ability of its products, write Tom Agan and Fred Geyer.
Latest:
Episode 28: Digital MedicineMichelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.
Latest:
Does Formulary Contracting = Patients Will Get Their Prescriptions?A look at the communication disconnect between contracting with managed care plans and pharmaceutical benefit managers (PBMs) and the imposition and implications of prior authorization (PA) requirements.
Latest:
Launch for Long-Term SuccessStudy examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Latest:
Launch for Long-Term SuccessStudy examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Latest:
Launch for Long-Term SuccessStudy examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Latest:
Launch for Long-Term SuccessStudy examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Latest:
Portfolio Management Health CheckFor pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.
Latest:
Episode 59: Using Tau to Target Alzheimer’sJanice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.
Latest:
AI-based Social Listening as Aid to PharmacovigilanceHow artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.
Latest:
Pharma Companies Can Solve the Social Media Adverse Events Reporting Problem and Stop WorryingOrganizations can now confidently leverage social media and messaging platforms to market and share content, writes Dawn Lacallade.
Latest:
Meaningful Insights with Graph TechnologyEmil Eifrem examines how life science researchers can uncover new insights using the in-built power of graph technology.
Latest:
What's Behind the Clinical Innovation Gap?In terms of important clinical benefits and outcomes, modern biotech products have rarely shown the advantages of older generations of drugs, writes Bagrat Lalayan.
